The XTEND-CIU study: long term use of Omalizumab in Chronic Idiopathic Urticaria

Publication date: Available online 10 November 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Marcus Maurer, Allen Kaplan, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L. Trzaskoma, Ming Yang, Thomas B. Casale
These data support omalizumab safety and efficacy in patients with antihistamine-resistant CIU/CSU to 48 weeks and provide evidence of omalizumab re-treatment efficacy and safety.



http://ift.tt/2jiPHKO